Jan 21 (Reuters) - GlaxoSmithKline PLC GSK.L :
* US FOOD AND DRUG ADMINISTRATION (FDA) GRANTS PRIORITY REVIEW OF BELANTAMAB MAFODOTIN FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
* GLAXOSMITHKLINE PLC - U.S. FDA GRANTED PRIORITY REVIEW FOR CO'S BIOLOGICS LICENSE APPLICATION SEEKING APPROVAL OF BELANTAMAB MAFODOTIN